These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
549 related articles for article (PubMed ID: 29180535)
1. Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells. Rudqvist NP; Pilones KA; Lhuillier C; Wennerberg E; Sidhom JW; Emerson RO; Robins HS; Schneck J; Formenti SC; Demaria S Cancer Immunol Res; 2018 Feb; 6(2):139-150. PubMed ID: 29180535 [TBL] [Abstract][Full Text] [Related]
2. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts. Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263 [TBL] [Abstract][Full Text] [Related]
3. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity. Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075 [TBL] [Abstract][Full Text] [Related]
4. Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. Page DB; Yuan J; Redmond D; Wen YH; Durack JC; Emerson R; Solomon S; Dong Z; Wong P; Comstock C; Diab A; Sung J; Maybody M; Morris E; Brogi E; Morrow M; Sacchini V; Elemento O; Robins H; Patil S; Allison JP; Wolchok JD; Hudis C; Norton L; McArthur HL Cancer Immunol Res; 2016 Oct; 4(10):835-844. PubMed ID: 27587469 [TBL] [Abstract][Full Text] [Related]
5. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484 [TBL] [Abstract][Full Text] [Related]
6. TCR repertoire intratumor heterogeneity of CD4 Zhang C; Ding H; Huang H; Palashati H; Miao Y; Xiong H; Lu Z Int J Cancer; 2019 Feb; 144(4):818-827. PubMed ID: 30151844 [TBL] [Abstract][Full Text] [Related]
7. Persistence and enrichment of dominant T cell clonotypes in expanded tumor-infiltrating lymphocytes of breast cancer. Ham B; Kim SY; Kim YA; Han D; Park T; Cha S; Jung S; Kim JH; Park G; Gong G; Lee HJ; Shin J Br J Cancer; 2024 Jul; 131(1):196-204. PubMed ID: 38750113 [TBL] [Abstract][Full Text] [Related]
8. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer. Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077 [TBL] [Abstract][Full Text] [Related]
9. Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity. Leshem Y; O'Brien J; Liu X; Bera TK; Terabe M; Berzofsky JA; Bossenmaier B; Niederfellner G; Tai CH; Reiter Y; Pastan I Cancer Immunol Res; 2017 Aug; 5(8):685-694. PubMed ID: 28674083 [TBL] [Abstract][Full Text] [Related]
11. TCR Repertoire Analysis Reveals Mobilization of Novel CD8 Aoki H; Ueha S; Shichino S; Ogiwara H; Hashimoto SI; Kakimi K; Ito S; Matsushima K Front Immunol; 2018; 9():3185. PubMed ID: 30733724 [TBL] [Abstract][Full Text] [Related]
12. CTLA-4 blockade boosts the expansion of tumor-reactive CD8 Friese C; Harbst K; Borch TH; Westergaard MCW; Pedersen M; Kverneland A; Jönsson G; Donia M; Svane IM; Met Ö Sci Rep; 2020 Mar; 10(1):3914. PubMed ID: 32127601 [TBL] [Abstract][Full Text] [Related]
13. TCR function analysis using a novel system reveals the multiple unconventional tumor-reactive T cells in human breast cancer-infiltrating lymphocytes. Yamaguchi S; Hamana H; Shitaoka K; Sukegawa K; Nagata T; Hayee A; Kobayashi E; Ozawa T; Fujii T; Muraguchi A; Tobe K; Kishi H Eur J Immunol; 2021 Sep; 51(9):2306-2316. PubMed ID: 34171120 [TBL] [Abstract][Full Text] [Related]
14. Relationship between T cell receptor clonotype and PD-1 expression of tumor-infiltrating lymphocytes in colorectal cancer. Sukegawa K; Shitaoka K; Hamana H; Kobayashi E; Miyahara Y; Fujii K; Tsuda K; Saeki S; Nagata T; Ozawa T; Saito S; Fujii T; Muraguchi A; Shiku H; Kishi H Eur J Immunol; 2020 Oct; 50(10):1580-1590. PubMed ID: 32441316 [TBL] [Abstract][Full Text] [Related]
15. The T-cell receptor repertoire of tumor-infiltrating regulatory T lymphocytes is skewed toward public sequences. Sainz-Perez A; Lim A; Lemercier B; Leclerc C Cancer Res; 2012 Jul; 72(14):3557-69. PubMed ID: 22573714 [TBL] [Abstract][Full Text] [Related]